SCHEMBL3607811

SCHEMBL3607811

COc1ccc(N(S)C(N)=O)c(C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 7/20 0.43
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPK10 P53779 1/20 0.38
ALOX5 P09917 2/20 0.38
AKR1C3 P42330 2/20 0.38
AKR1C2 P52895 2/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
ATM Q13315 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
AKR1C4 P17516 1/20 0.38
AKR1C1 Q04828 1/20 0.38
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
PARP1 P09874 1/20 0.37
PARP10 Q53GL7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2590633 0.79 CA12 (0.48) ALDH1A1TSHRALOX5LMNAGAA
SCHEMBL3604278 0.79 POLB (0.42) TSHRALOX5GAASMN1; SMN2CA1
SCHEMBL14662766 0.76 POLB (0.42) ALDH1A1HSD17B10ALOX5GAAMAPT
SCHEMBL5460005 0.74 MAPK10 (0.53) EPHX2ALDH1A1TSHRHSD17B10MAPK10
SCHEMBL14053642 0.73 LMNA (0.40) ALDH1A1LMNAGAA
SCHEMBL30087611 0.73 EPHX2 (0.47) EPHX2ALDH1A1TSHRHSD17B10MAPK10
SCHEMBL2749288 0.72 AKR1C3 (0.36) ALDH1A1ALOX5AKR1C3AKR1C2MAPT
SCHEMBL6114202 0.71 MAPT (0.43) ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL30938335 0.71 MAPK10 (0.50) EPHX2ALDH1A1TSHRHSD17B10MAPK10
SCHEMBL1983309 0.70 AKR1C3 (0.53) EPHX2ALDH1A1AKR1C3AKR1C2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1687285-B1 THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS NOVARTIS AG (CH) 2014-03-05 EP disclosed
US-7795288-B2 Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors NOVARTIS AG (CH) 2010-09-14 US disclosed
US-20070167449-A1 Thiazole and pyrazole derivatives as flt-3 kinase inhibitors NOVARTIS PHARMA AG (CH) 2007-07-19 US disclosed
EP-1687285-A1 THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS Novartis AG (CH) 2006-08-09 EP disclosed
WO-2005047273-A1 THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS NOVARTIS AG (CH) 2005-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167449-A1 Thiazole and pyrazole derivatives as flt-3 kinase inhibitors FLT3, FLT1, FLT4 EPHX2 2944/4885ALDH1A1 2488/4885TSHR 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.